{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:50:53Z","timestamp":1793875853845,"version":"4.7.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"SI","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Clinician Scientist Program of the medical faculty"},{"name":"University of Tuebingen","award":["477-0-0"],"award-info":[{"award-number":["477-0-0"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the feasibility of reduced cyclophosphamide dosing in the setting of mobilization chemotherapy prior to high dose chemotherapy and autologous stem cell transplantation in patients with SSc. The primary end point was the occurrence of \u2018poor mobilization\u2019 when using different cyclophosphamide dosing. The second end point was to analyse potential risk factors for difficult stem cell mobilization in this cohort of patients with SSc.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-centre study retrospectively reviewed 32 patients with SSc who underwent autologous stem cell transplantation. We analysed the occurrence of \u2018poor mobilization\u2019 (defined as CD34+ progenitor cell count &amp;lt;2\u2009\u00d7\u2009106\/kg body weight, the use of increasing G-CSF dose, the use of plerixafor, or leukapheresis on &amp;gt;2 consecutive days) in different cyclophosphamide mobilization regimens: We herein compared low dose (2\u2009\u00d7\u20091\u20131.5\u2009g\/m2) cyclophosphamide vs high dose (2\u2009\u00d7\u20092\u2009g\/m2) for mobilization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Higher dosing of cyclophosphamide seems not to be beneficial regarding stem cell collection as there was no significant difference in stem cell yield between high dose and reduced dose cyclophosphamide (6.2 vs 5.2\u2009\u00d7\u2009106\/kg bodyweight after CD34+ enrichment). Furthermore, higher doses of cyclophosphamide might be associated with more side effects; this difference was, however, not statistically significant. Lower bodyweight and BMI (P\u2009&amp;lt;\u20090.001) as well as rituximab pre-therapy (P\u2009&amp;lt;\u20090.05) and cardiac involvement (P\u2009&amp;lt;\u20090.01) might negatively impact stem cell collection independently from the chosen regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our data demonstrate that a reduced cyclophosphamide mobilization regimen seems to be feasible. Risk factors for poor mobilization might be low bodyweight, prior rituximab therapy and cardiac involvement.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac455","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T18:26:58Z","timestamp":1660242418000},"page":"SI107-SI113","source":"Crossref","is-referenced-by-count":8,"title":["Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-0686","authenticated-orcid":false,"given":"Ann-Christin","family":"Pecher","sequence":"first","affiliation":[{"name":"Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases, University Hospital Tuebingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina Renate","family":"Ach","sequence":"additional","affiliation":[{"name":"Eberhard-Karls-University Tuebingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen , Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8385-6861","authenticated-orcid":false,"given":"Joerg Christoph","family":"Henes","sequence":"additional","affiliation":[{"name":"Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases, University Hospital Tuebingen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"2023020607512914900_keac455-B1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023020607512914900_keac455-B2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2023020607512914900_keac455-B3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"2023020607512914900_keac455-B4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"},{"key":"2023020607512914900_keac455-B5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3899\/jrheum.110868","article-title":"Optimization of autologous stem cell transplantation for systemic sclerosis \u2013 a single-center longterm experience in 26 patients with severe organ manifestations","volume":"39","author":"Henes","year":"2012","journal-title":"J Rheumatol"},{"key":"2023020607512914900_keac455-B6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"2023020607512914900_keac455-B7","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"2023020607512914900_keac455-B8","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1371\/journal.pone.0001452","article-title":"Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?","volume":"3","author":"Fleming","year":"2008","journal-title":"PLoS One"},{"key":"2023020607512914900_keac455-B9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"2023020607512914900_keac455-B10","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023020607512914900_keac455-B11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13023-021-01844-y","article-title":"French recommendations for the management of systemic sclerosis","volume":"16","author":"Hachulla","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2023020607512914900_keac455-B12","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3389\/fimmu.2018.02390","article-title":"Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis","volume":"9","author":"Del Papa","year":"2018","journal-title":"Front Immunol"},{"key":"2023020607512914900_keac455-B13","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/WNL.54.11.2147","article-title":"Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor","volume":"54","author":"Openshaw","year":"2000","journal-title":"Neurology"},{"key":"2023020607512914900_keac455-B14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.56.6.364","article-title":"Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice","volume":"56","author":"Campbell","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"2023020607512914900_keac455-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1703081","article-title":"Collection of hematopoietic stem cells from patients with autoimmune diseases","volume":"28","author":"Burt","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2023020607512914900_keac455-B16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","article-title":"Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2023020607512914900_keac455-B17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2023020607512914900_keac455-B18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ejh.12686","article-title":"Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease","volume":"97","author":"Blank","year":"2016","journal-title":"Eur J Haematol"},{"key":"2023020607512914900_keac455-B19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.bmt.1704106","article-title":"Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients","volume":"32","author":"Benekli","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"2023020607512914900_keac455-B20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.bmt.1705649","article-title":"Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma","volume":"39","author":"Kamezaki","year":"2007","journal-title":"Bone Marrow Transplant"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac455\/45348324\/keac455.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI\/SI107\/49085119\/keac455.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI\/SI107\/49085119\/keac455.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T07:51:49Z","timestamp":1675669909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/SI\/SI107\/6661361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":20,"journal-issue":{"issue":"SI","published-online":{"date-parts":[[2022,8,11]]},"published-print":{"date-parts":[[2023,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac455","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,8,11]]}}}